MAZ and neoplasm: The tumor/liver ratio was significantly higher (5.1-fold and 4.5-fold, respectively) in the DBCO–anti–4-1BB plus MazNP group than in the DBCO–anti–4-1BB plus free Maz or anti–4-1BB groups (Figure 7E).